EP 131: Beyond Weight Loss: GLP-1s as Cardioprotective Game-Changers in 2025

In this episode of Parallax, host Dr Ankur Kalra sits down with Dr Ambarish Pandey to explore the transformative role of GLP-1 receptor agonists in cardiovascular medicine. Beyond their well-known effects on weight management, Dr Pandey reveals how these "blockbuster drugs" are fundamentally reshaping cardiovascular disease prevention and treatment, with compelling evidence from the landmark SELECT trial. The discussion navigates through real-world clinical scenarios where GLP-1s deliver significant cardiovascular benefits, from post-acute coronary events to established atherosclerotic disease. Dr Pandey provides nuanced, evidence-based recommendations for GLP-1 therapy across various heart failure phenotypes, while addressing common comorbidities like atrial fibrillation and obstructive sleep apnea. Recognizing practical challenges, the conversation offers actionable strategies for medication initiation, dose optimization, and navigating insurance hurdles. The episode concludes with an exciting look toward emerging frontiers, including GLP-1 benefits in chronic kidney disease and innovative metabolic accelerators that could complement existing therapies. For clinicians seeking to optimize cardio-metabolic care in 2025, this discussion provides essential insights into both current best practices and promising therapeutic horizons. Disclosures: Dr Ambarish Pandey is a consultant for Novo Nordisk, Eli Lilly, Roche, and Rivus Pharma. Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCARDIO Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts: https://www.radcliffecardiology.com/news/parallax-podcast-ankur-kalra-recognised-among-top-medical-podcasts?language_content_entity=en